Biopharmas Manage To Deal During Pandemic
BY JOSEPH HAAS Executive Summary M&A activity faces numerous hurdles during the COVID-19 pandemic but companies are finding different ways to negotiate, conduct due diligence and get deals completed, BIO 2020 speakers said.
34 / September 2020
Biopharma deal-making has continued at a steady pace during the novel coronavirus pandemic – helped by frequent transactions related to COVID-19 – but the industry also is getting more used to the limitations imposed by social distancing, speakers said on panel at BIO’s digital meeting. The drivers underlying deal-making remain unchanged – big pharma and other players need new pipeline assets and remain very interested in novel technologies – Prakash Raman, senior partner and chief business development officer at Flagship Pioneering, said during a session on what companies are looking for in acquisitions. Although not billed as a session specific to the impact of the pandemic, much of the discussion centered on how deals are being negotiated and finalized in this different environment for business.
© Informa UK Ltd 2020 (Unauthorized photocopying prohibited.)
